Connect with us

Health

Cancer Leagues call for overhaul of EU drug pricing transparency rules

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

In a new report, ‘Behind the Price Tag’, the Association of European Cancer Leagues (ECL) has renewed calls for a major overhaul of the EU’s pharmaceutical pricing rules, arguing that the EU’s long-standing Transparency Directive no longer reflects the realities of today’s medicines market.

"The Directive has not evolved with the pharmaceutical market and risks becoming increasingly disconnected from its realities. A comprehensive revision is now essential," says ECL Executive Director, Wolfgang Fecke.

Adopted in 1989, the Transparency Directive aimed to ensure that national decisions on the pricing and reimbursement of medicines were transparent, predictable, and delivered within set timelines.

More than three decades later, however, the pharmaceutical landscape has changed dramatically. Confidential disc...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending